Jeff Yass’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-10,154
Closed -$161K – 14212
2026
Q2
$161K Sell
10,154
-15,026
-60% -$242K ﹤0.01% 12147
2026
Q1
$331K Buy
25,180
+15,059
+149% +$226K ﹤0.01% 10656
2025
Q4
$156K Buy
+10,121
New +$135K ﹤0.01% 11131
2025
Q3
– Sell
-29,197
Closed -$275K – 13418
2025
Q2
$325K Buy
29,197
+9,288
+47% +$116K ﹤0.01% 10157
2025
Q1
$245K Buy
19,909
+7,295
+58% +$91.3K ﹤0.01% 10515
2024
Q4
$141K Buy
+12,614
New +$110K ﹤0.01% 11065
2024
Q2
– Sell
-203,776
Closed -$2.06M – 12858
2024
Q1
$2.69M Buy
203,776
+161,491
+382% +$2.3M ﹤0.01% 4719
2023
Q4
$436K Buy
+42,285
New +$337K ﹤0.01% 9001
2023
Q2
– Sell
-14,052
Closed -$65.2K – 12793
2023
Q1
$65.2K Buy
+14,052
New +$53.8K ﹤0.01% 11568

Other funds holding NPCE

Jeff Yass's NPCE Position: Q3 2026 in Review

Jeff Yass sold out of Neuropace (NPCE) in Q3 2026, closing a stake of 10,154 shares — an estimated $161K sold.

Jeff Yass first reported a position in NPCE in Q1 2023 and held it in 9 quarters. The position peaked at $2.69M in Q1 2024. 105 funds tracked by Wall St. Rank hold NPCE as of Q3 2026.

  • Jeff Yass reported no remaining Neuropace position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 10,154 Neuropace shares in Q3 2026, an estimated $161K.
  • Jeff Yass first reported a position in Neuropace in Q1 2023 and held it in 9 quarters.
  • Jeff Yass's Neuropace position peaked at $2.69M in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Neuropace as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.